SCHEMBL3907941

SCHEMBL3907941

Cc1ccc(S(=O)(=O)Nc2ccc3c(c2)c(=O)[nH]n3CCc2ccccc2)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 5/20 0.48
PDE3A Q14432 1/20 0.44
MAPT P10636 5/20 0.44
TP53 P04637 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
GAA P10253 1/20 0.42
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
BRD1 O95696 2/20 0.42
BRPF1 P55201 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NR1I2 O75469 1/20 0.41
LMNA P02545 2/20 0.41
RECQL P46063 1/20 0.41
MLNR O43193 1/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
HTR6 P50406 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1843607 0.92 PKM (0.50) PKMPDE3AMAPTTP53SMN1; SMN2
SCHEMBL3917146 0.87 HSD17B1 (0.45) PKMMAPTTP53BRPF1MEN1
SCHEMBL1811589 0.86 TRIM24 (0.50) PDE3AMAPTTP53BRD1BRPF1
SCHEMBL3904770 0.83 NR1I2 (0.43) PKMMAPTDDB1CRBNMEN1
SCHEMBL3916446 0.83 BRD4 (0.41) PKMMAPTTP53SMN1; SMN2GAA
SCHEMBL3909458 0.83 PKM (0.51) PKMMAPTTP53SMN1; SMN2TDP1
SCHEMBL3903013 0.83 NR1I2 (0.39) PDE3AMAPTMEN1KMT2ANR1I2
SCHEMBL3915102 0.80 PTGDR2 (0.48) PKMPDE3AMAPTMEN1KMT2A
SCHEMBL3917148 0.80 NR3C1 (0.48) MAPTGAAMEN1KMT2AHTR6
SCHEMBL1813239 0.79 NR1I2 (0.60) PDE3AMAPTMEN1KMT2ANR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
EP-1797042-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-06-20 EP disclosed
WO-2006034804-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-04-06 WO disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 PKM 1481/4885PDE3A 206/4885MAPT 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.